Decoding Linehan There is an old story in the hockey world about the Edmonton Oilers dynasty. When they were just starting out together as a group of kids, they had to climb their way to the top of the league. Sitting at the top was the old dynasty, the New York Islanders, who were winning their fourth straight title at the expense of Wayne Gretzky and those kids from Edmonton in the 1983 Stanley Cup Finals. The young Oilers were disappointed that they hadn't quite figured things out in losing to the old Islanders, but they knew they were close. That idea was cemented in their heads when they walked by the winners' dressing room and didn't see a celebration, but rather 20 exhausted guys with
Josh Hamilton is still owed a lot of money. After playing in just one minor-league game in 2016, outfielder Josh Hamilton is ready to make a comeback. While that seems like a far cry from what Hamilton was making in his prime, that’s not exactly the case.
When the first wave of purported and admitted steroids users began appearing on the Baseball Hall of Fame ballot a decade ago, voters rejected them overwhelmingly, no matter their credentials. Drug-tainted sluggers Mark McGwire and Rafael Palmeiro garnered only paltry support, eventually falling off the ballot, while Sammy Sosa could soon meet the same fate. All three boast career statistics that have historically merited induction into the Cooperstown, N.Y., museum. But when results from this year’s Hall of Fame balloting are announced Wednesday, a far different picture is expected to emerge, one that reflects the voting body’s rapidly loosening attitudes toward performance-enhancing drug use.